(Reuters) - The judge found that the three companies grossly inflated
the prices of drugs, including chemotherapy agents, to the
detriment of the U.S. government's Medicare program for the
elderly, insurance companies and individuals.
Plaintiffs in the class-action lawsuit said the drug makers
boosted published average wholesale prices, which until 2003
were the basis for reimbursements from Medicare, state
governments and private insurers. The marked-up prices created
a spread between a doctor or pharmacy's real cost and the
drug's published cost.
Read more at Reuters.com Bonds News
the prices of drugs, including chemotherapy agents, to the
detriment of the U.S. government's Medicare program for the
elderly, insurance companies and individuals.
Plaintiffs in the class-action lawsuit said the drug makers
boosted published average wholesale prices, which until 2003
were the basis for reimbursements from Medicare, state
governments and private insurers. The marked-up prices created
a spread between a doctor or pharmacy's real cost and the
drug's published cost.
Read more at Reuters.com Bonds News
No comments:
Post a Comment